Immuneering (IMRX) Revenue (2020 - 2022)

Immuneering's Revenue history runs 3 years deep, the most recent figure standing at $455.0 for Q4 2022.

• On a quarterly basis, Revenue fell 99.76% year-over-year to $455.0 in Q4 2022; TTM through Sep 2023 was $455.0, a 99.91% decrease from a year earlier, with the FY2022 full-year figure at $316952.0, down 84.76% from the prior year.
• Revenue eased to $455.0 in Q4 2022 per IMRX's latest filing, from $38380.0 in the prior quarter.
• Across five years, Revenue topped out at $748200.0 in Q1 2021 and bottomed at $455.0 in Q4 2022.
• The 3-year median for Revenue is $480835.0 (2020), against an average of $384127.1.
• Across the five-year window, Revenue soared 37.27% in 2021 and plunged 99.76% in 2022, its largest moves.
• Year by year, Revenue stood at $665080.0 in 2020, then slumped by 71.49% to $189591.0 in 2021, then plunged by 99.76% to $455.0 in 2022.
• Per Business Quant, the three latest IMRX Revenue figures stand at $455.0 (Q4 2022), $38380.0 (Q3 2022), and $94419.0 (Q2 2022).